Key facts
- Notable investors include JITO Incubation & Innovation Foundation, Rebalance Accelerator, Sunicon Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Akrivia Biomedics
- ·The full record, as it builds
Funding rounds
No funding rounds for Akrivia Biomedics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Akrivia Biomedics
Developer of a multi-omics decision support platform designed to interpret cancer data and reveal tumour biology. The company's platform offers integration of DNA and RNA data, programme-aware tumour profiling, tiered tumour state modelling, and clinician-ready reporting, enabling oncologists, researchers, and pharmaceutical teams to understand tumour behaviour and support clinical decision making.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 3
- Website
- akriviabiomedics.co.uk/
- Ownership
- Privately Held (backing)
Akrivia Biomedics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akrivia Biomedics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akrivia Biomedics in its N-PORT filings yet. We sweep new filings monthly.